{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T10:42:21Z","timestamp":1769942541765,"version":"3.49.0"},"reference-count":57,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T00:00:00Z","timestamp":1733788800000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Discovery"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Metronomic chemotherapy (MC) is an innovative therapeutic approach that involves the chronic administration of low doses of chemotherapy agents. This strategy aims to sustain prolonged and active plasma levels of drugs, which can result in favorable tolerability. MC has shown promise in the treatment of hematologic and solid tumors, including high\u2010risk neuroblastoma and relapsed\/refractory (R\/R) neuroblastoma. In the contemporary management of neuroblastoma, MC stands as a viable maintenance therapy for newly diagnosed patients lacking access to autologous stem cell transplantation or immunotherapy, particularly in resource\u2010constrained regions. Furthermore, it serves as a pragmatic alternative for individuals intolerant to intensified regimens or undergoing palliative care for R\/R neuroblastoma. Nevertheless, the quest for the optimal MC regimen persists, necessitating comprehensive investigations to delineate standardized protocols. Moreover, the identification of potential biomarkers or prognostic indicators assumes paramount significance in refining MC strategies for future breakthroughs in this domain. This review embarks on a comprehensive exploration of MC in neuroblastoma, offering insights into its historical underpinnings, diverse applications, adverse effect and future prospects, endeavoring to enrich our understanding of MC role in neuroblastoma management.<\/jats:p>","DOI":"10.1002\/pdi3.2512","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T12:09:47Z","timestamp":1733832587000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Metronomic chemotherapy in pediatric neuroblastoma"],"prefix":"10.1002","volume":"2","author":[{"given":"Yi","family":"Jiang","sequence":"first","affiliation":[{"name":"Department of Surgical Oncology National Clinical Research Center for Child Health and Disorders Ministry of Education Key Laboratory of Child Development and Disorders China International Science and Technology Cooperation Base of Child Development and Critical Disorders Children's Hospital of Chongqing Medical University  Chongqing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengjun","family":"Xi","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology National Clinical Research Center for Child Health and Disorders Ministry of Education Key Laboratory of Child Development and Disorders China International Science and Technology Cooperation Base of Child Development and Critical Disorders Children's Hospital of Chongqing Medical University  Chongqing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7023-3577","authenticated-orcid":false,"given":"Chao","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology National Clinical Research Center for Child Health and Disorders Ministry of Education Key Laboratory of Child Development and Disorders China International Science and Technology Cooperation Base of Child Development and Critical Disorders Children's Hospital of Chongqing Medical University  Chongqing China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,12,10]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1369"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI9872"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon.15.306"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2014.89"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.6595"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2017.02.005"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2014.12.039"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.64"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2015.01.008"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2006.03.023"},{"issue":"2","key":"e_1_2_14_12_1","first-page":"117","article-title":"Concomitant radiotherapy and metronomic temozolomide in pediatric high\u2010risk brain tumors","volume":"49","author":"Sterba J","year":"2002","journal-title":"Neoplasma"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mph.0000183863.10792.d4"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mph.0000243657.64056.c3"},{"issue":"7","key":"e_1_2_14_15_1","first-page":"308","article-title":"Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: single\u2010center pilot study","volume":"29","author":"Sterba J","year":"2006","journal-title":"Onkologie"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2017.1285230"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30934"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.10.3221"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.358"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22821"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.04.012"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.4103\/0019-509X.118741"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1159\/000336483"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24794"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.0324"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.3747\/co.23.2873"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28508"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e3182018ab8"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27693"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13143494"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1268645"},{"key":"e_1_2_14_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.104995"},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14122985"},{"key":"e_1_2_14_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(05)70291-6"},{"key":"e_1_2_14_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-21"},{"key":"e_1_2_14_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30572"},{"key":"e_1_2_14_37_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.11642"},{"key":"e_1_2_14_38_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3909"},{"issue":"7","key":"e_1_2_14_39_1","first-page":"1878","article-title":"Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug\u2010resistant cancer","volume":"60","author":"Browder T","year":"2000","journal-title":"Cancer Res"},{"key":"e_1_2_14_40_1","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.48393"},{"key":"e_1_2_14_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2017.04.008"},{"key":"e_1_2_14_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26192"},{"key":"e_1_2_14_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30355-8"},{"key":"e_1_2_14_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02875"},{"key":"e_1_2_14_45_1","doi-asserted-by":"publisher","DOI":"10.1080\/08880018.2017.1373314"},{"key":"e_1_2_14_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.03.032"},{"key":"e_1_2_14_47_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11102849"},{"key":"e_1_2_14_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25501"},{"key":"e_1_2_14_49_1","first-page":"1","article-title":"Metronomic chemotherapy for children in low\u2010 and middle\u2010income countries: survey of current practices and opinions of pediatric oncologists","volume":"5","author":"Revon\u2010Rivi\u00e8re G","year":"2019","journal-title":"J Glob Oncol"},{"key":"e_1_2_14_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27811"},{"key":"e_1_2_14_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/apa.13338"},{"key":"e_1_2_14_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25900"},{"key":"e_1_2_14_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20380"},{"key":"e_1_2_14_54_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-005-1093-6"},{"key":"e_1_2_14_55_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0235"},{"key":"e_1_2_14_56_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-010-0807-x"},{"key":"e_1_2_14_57_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12904"},{"key":"e_1_2_14_58_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3984"}],"container-title":["Pediatric Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pdi3.2512","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,25]],"date-time":"2024-12-25T02:21:38Z","timestamp":1735093298000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pdi3.2512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1002\/pdi3.2512"],"URL":"https:\/\/doi.org\/10.1002\/pdi3.2512","archive":["Portico"],"relation":{},"ISSN":["2835-558X","2835-5598"],"issn-type":[{"value":"2835-558X","type":"print"},{"value":"2835-5598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"2024-05-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2512"}}